News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Geron Corporation Initiates Clinical Trial of GRN163L in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
October 20, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced that it has enrolled the first multiple myeloma patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in combination with other treatments.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
MORE ON THIS TOPIC
Rare diseases
Argenx Eyes ‘Broadest Label’ for Vyvgart in Myasthenia Gravis After Positive Phase III Data
August 26, 2025
·
2 min read
·
Tristan Manalac
Podcast
Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations
August 26, 2025
·
1 min read
·
Jef Akst
Regulatory
Krystal Cuts Melanoma Study of Viral Immunotherapy as FDA ‘Uncertainty’ Muddies Approval Pathway
August 22, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
With Prasad Back at FDA, Capricor To Fight DMD Cardiomyopathy Rejection
August 20, 2025
·
7 min read
·
Heather McKenzie
